Drug intelligence / Profile preview

CS1016

Development stage: Preclinical
Lead developer: CStone Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

CS1016 is a PD-1 agonist monoclonal antibody being developed by CStone Pharmaceuticals for the treatment of autoimmune and inflammatory diseases. Unlike conventional PD-1 antagonists used in oncology to block the PD-1/PD-L1 checkpoint and activate T cells, CS1016 acts as an agonist to activate the PD-1 pathway. This activation serves to suppress overactive immune responses, making it a potential therapeutic for various immunology indications. As of 2026, the drug is part of CStone's Pipeline 2.0 and is in early-stage development.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on CS1016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS1016.

Explore the full profile